Zydus Cadila gets approval for phase III clinical trials from DCGI

Zydus Cadila on Sunday said it has received DCGI approval to start Phase III clinical trials of its COVID-19 vaccine ZyCoV-D. The company will initiate Phase III clinical trials in around 30,000 volunteers. The phase II study of ZyCoV-D had been conducted in over 1,000 healthy adult volunteers. “The launch of the Phase 3 trial will determine the efficacy of the company’s vaccine in preventing COVID-19, which continues to pose a major threat world over” said Zydus Group Chairman Pankaj R Patel.